Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women aged 18 to 75 years who have given written consent before any trial procedures begin
• People with cervical cancer that has been confirmed by a tissue or cell sample, specifically one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
• People whose cervical cancer has come back locally or spread to a limited number of sites after initial treatment (no more than 5 areas total, with specific limits on how many spots are in the lymph nodes, liver, or lungs)
• People who are generally well enough to carry out daily activities with little or no limitation (confirm with trial site regarding the specific fitness scale used)
• People who have at least one area of cancer that can be treated with radiotherapy and measured on scans
• People who have a tumor tissue sample available for testing
• People whose doctors expect them to live at least 6 months
• People whose blood counts, liver, kidney, thyroid, and heart function are within acceptable ranges based on blood tests taken within 7 days before joining
• People whose side effects from any previous cancer treatment have mostly resolved before starting the trial (with some exceptions such as hair loss, mild skin changes, or mild nerve symptoms)
• Women who could become pregnant must be using an approved form of contraception, have a negative pregnancy test within 7 days before joining, and must not be breastfeeding
• People who are expected to be able to attend follow-up visits as required by the trial

Who may not be able to join:

• People who have previously received immunotherapy, such as immune checkpoint inhibitor drugs
• People whose cervical cancer has been identified as a specific subtype called gastric-type adenocarcinoma
• People who have an active autoimmune disease or a history of autoimmune conditions (such as autoimmune liver disease, certain lung conditions, eye inflammation, bowel inflammation, or thyroid problems) — some exceptions may apply (confirm with trial site)
• People currently taking immune-suppressing medications or steroid medicines above a certain dose within the 2 weeks before joining
• People who experienced severe (Grade 3 or 4) immune-related side effects from previous cancer immunotherapy
• People with poorly controlled heart conditions, such as moderate-to-severe heart failure, unstable chest pain, a heart attack within the past 6 months, certain heart rhythm problems, or an abnormal heart electrical reading above a specified level
• People with blood clotting problems, a tendency to bleed, or who are currently on blood-thinning or clot-dissolving medications
• People who completed previous cancer treatments (such as radiotherapy, chemotherapy, surgery, or targeted therapy) less than 4 weeks before starting this trial, or who still have unresolved side effects from those treatments
• People with significant fluid build-up in body cavities that requires draining before treatment begins
• People who have coughed up a significant amount of blood (2.5 mL or more per day) in the 2 months before joining
• People with known inherited or acquired bleeding or clotting disorders (such as haemophilia or a low platelet condition)
• People with an active infection or an unexplained fever above 38.5°C at the time of screening or before the first dose
• People with confirmed lung scarring, certain types of lung inflammation, or severely reduced lung function
• People with a weakened immune system (such as HIV infection) or active hepatitis B or C, based on blood test results
• People who have taken part in another clinical drug trial within 4 weeks before the first dose, or who have had radiotherapy or local treatment without full recovery within 2 weeks before joining
• People who have had another type of cancer, except for certain fully treated skin cancers or cervical pre-cancer
• People who are planned to receive other systemic cancer treatments at the same time as this trial
• People who have received a live vaccine within 4 weeks before starting treatment, or who plan to receive one during the trial
• People with serious other health conditions (including certain mental health conditions), severely abnormal lab results, or personal or family circumstances that could affect their safety or the reliability of the trial data, based on the trial doctor's judgment

Important: Always verify eligibility with the trial site directly before applying.